Cannerald: Hemp plant sites should yield up to 30 percent return - now the company is insolvent
Tens of thousands of investors bet on the cannabis start-up Cannerald. Now, the Swiss have sold their production facilities and filed for bankruptcy. Investors are fearing losses of up to 100 million euros.
Swiss company Cannerald, which produces medical cannabis, is set to have bankruptcy proceedings opened against it by the Bern-Mittelland court. The company announced this to its customers, stating that it had sold its production facility in Fraubrunnen to another company at the end of September, but the buyer only acquired assets, not contracts with customers or liabilities.
The sale of the facility has made bankruptcy inevitable. The fate of payments made by tens of thousands of customers who bought cannabis plants from Cannerald remains uncertain. The bankruptcy court will soon invite customers and business partners to register their individual claims.
Written by urgent.news from Handelsblatt's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.